Michael Dill
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) (NCT05690048) | Michael Dill | 2025-07-16 |
Track Michael Dill automatically
Every clearance here is in the API, with alerts when new ones post.